KR20240046498A - Brm의 조절에 사용하기 위한 페놀 유도체 - Google Patents
Brm의 조절에 사용하기 위한 페놀 유도체 Download PDFInfo
- Publication number
- KR20240046498A KR20240046498A KR1020247004828A KR20247004828A KR20240046498A KR 20240046498 A KR20240046498 A KR 20240046498A KR 1020247004828 A KR1020247004828 A KR 1020247004828A KR 20247004828 A KR20247004828 A KR 20247004828A KR 20240046498 A KR20240046498 A KR 20240046498A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- pharmaceutically acceptable
- compound
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231220P | 2021-08-09 | 2021-08-09 | |
| US202163231219P | 2021-08-09 | 2021-08-09 | |
| US63/231,219 | 2021-08-09 | ||
| US63/231,220 | 2021-08-09 | ||
| PCT/US2022/039696 WO2023018648A1 (en) | 2021-08-09 | 2022-08-08 | Phenol derivatives for use in the modulation of brm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240046498A true KR20240046498A (ko) | 2024-04-09 |
Family
ID=83149068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247004828A Pending KR20240046498A (ko) | 2021-08-09 | 2022-08-08 | Brm의 조절에 사용하기 위한 페놀 유도체 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11993599B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4384517A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024533990A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240046498A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022328137A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3225467A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202321250A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023018648A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024533990A (ja) | 2021-08-09 | 2024-09-18 | ジェネンテック, インコーポレイテッド | Brmの調節に使用するためのフェノール誘導体 |
| JP2025525340A (ja) * | 2022-06-16 | 2025-08-05 | プレキシウム インコーポレイテッド | Swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily aを分解する化合物および医薬組成物 |
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| SG11202104495YA (en) | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| WO2019213005A1 (en) | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN112996800B (zh) | 2018-10-16 | 2024-06-25 | 勃林格殷格翰国际有限公司 | 作为smarca2和/或smarca4的降解剂的新型蛋白水解靶向嵌合体(protac)及其衍生物 |
| FR3090393B1 (fr) | 2018-12-20 | 2021-04-23 | Ifp Energies Now | Procédé de traitement d’une charge alcool pour la production d’oléfines |
| US20220143183A1 (en) | 2019-02-23 | 2022-05-12 | New York University | Photoswitchable protacs and synthesis and uses thereof |
| US20220324880A1 (en) * | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US20230087825A1 (en) * | 2019-06-10 | 2023-03-23 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| CA3150354A1 (en) | 2019-09-12 | 2021-03-18 | Muralidhara Ramachandra | METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS |
| JP7502425B2 (ja) * | 2019-10-01 | 2024-06-18 | アルヴィナス・オペレーションズ・インコーポレイテッド | Brm標的化化合物および関連使用方法 |
| EP4054724A4 (en) * | 2019-10-28 | 2023-12-27 | C4 Therapeutics, Inc. | BIFUNCTIONAL CONNECTIONS |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| CA3167166A1 (en) | 2020-01-10 | 2021-07-15 | Amgen Inc. | Smarca2-vhl degraders |
| JP7508578B2 (ja) | 2020-04-06 | 2024-07-01 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| PT4161935T (pt) * | 2020-06-09 | 2025-08-14 | Prelude Therapeutics Inc | Compostos direcionados a brm e métodos de utilização associados |
| IL299860A (en) * | 2020-07-21 | 2023-03-01 | Genentech Inc | Antibody-conjugated chemical factors for the discharge of BRM and their methods |
| US12552775B2 (en) | 2020-11-20 | 2026-02-17 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US20240150755A1 (en) | 2021-02-26 | 2024-05-09 | Salk Institute For Biological Studies | Modulating regulatory t cell function in autoimmune disease and cancer |
| JP2024533990A (ja) | 2021-08-09 | 2024-09-18 | ジェネンテック, インコーポレイテッド | Brmの調節に使用するためのフェノール誘導体 |
-
2022
- 2022-08-08 JP JP2024507995A patent/JP2024533990A/ja active Pending
- 2022-08-08 EP EP22761812.1A patent/EP4384517A1/en active Pending
- 2022-08-08 AU AU2022328137A patent/AU2022328137A1/en active Pending
- 2022-08-08 KR KR1020247004828A patent/KR20240046498A/ko active Pending
- 2022-08-08 US US17/883,004 patent/US11993599B2/en active Active
- 2022-08-08 WO PCT/US2022/039696 patent/WO2023018648A1/en not_active Ceased
- 2022-08-08 CA CA3225467A patent/CA3225467A1/en active Pending
- 2022-08-09 TW TW111129895A patent/TW202321250A/zh unknown
-
2024
- 2024-03-13 US US18/604,314 patent/US12428419B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240383897A1 (en) | 2024-11-21 |
| US20230112485A1 (en) | 2023-04-13 |
| US11993599B2 (en) | 2024-05-28 |
| WO2023018648A1 (en) | 2023-02-16 |
| EP4384517A1 (en) | 2024-06-19 |
| JP2024533990A (ja) | 2024-09-18 |
| TW202321250A (zh) | 2023-06-01 |
| US12428419B2 (en) | 2025-09-30 |
| CA3225467A1 (en) | 2023-02-16 |
| AU2022328137A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7603609B2 (ja) | アンドロゲン受容体を標的に分解する二官能性キメラ複素環式化合物及びその使用 | |
| AU2020232026B2 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
| US10988478B1 (en) | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | |
| JP7041198B2 (ja) | Jak阻害剤である5-クロロ-2-ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| ES2829636T3 (es) | Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso | |
| US20210269433A1 (en) | Bcl-2 inhibitors | |
| CN102918043B (zh) | 作为cdk4/6抑制剂的吡咯并嘧啶化合物 | |
| US12428419B2 (en) | Therapeutic compounds | |
| CA2889526C (en) | 2-aminopyridine compounds | |
| EA019785B1 (ru) | Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение | |
| TW202330548A (zh) | 用於降解egfr激酶的化合物 | |
| JP2025538190A (ja) | Egfrキナーゼの分解のための化合物 | |
| EP3546458B1 (en) | ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer | |
| US20250051344A1 (en) | Bifunctional selective degraders of smarca2 and therapeutic uses thereof | |
| CN117794933A (zh) | 用于调节brm的酚衍生物 | |
| HK40111551A (en) | Phenol derivatives for use in the modulation of brm | |
| WO2025076088A1 (en) | Lactams for use as sarm1 inhibitors | |
| EA050708B1 (ru) | Деградация тирозинкиназы брутона (btk) посредством конъюгации ингибиторов btk с лигандом лигазы е3 и способы применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |